ฝัง
- เผยแพร่เมื่อ 23 เม.ย. 2024
- Guests: Lachlan MacKinnon & Adrian Woolfson @ Replay Bio
Lachlan MacKinnon - Co-Founder and Chief Executive Officer
Lachlan is the Co-founder and CEO of Replay. He was previously a founding Principal at Oxford Science Enterprises (formerly OSI) where he made seed investments in companies at the intersection of technology and biology including investing the first capital in ONI, OMass Therapeutics, Nucleome Therapeutics, Spybiotech and Base Genomics. Base Genomics was acquired for $410m four months after an $11m seed financing, creating the largest ever IRR for a life sciences deal. He is also a Director of Depixus, a DNA/RNA sequencing company. He has an MA in Chemistry from the University of Oxford.
_______________________
Adrian Woolfson, BM BCh PhD - Co-Founder, Executive Chairman, and President
Adrian Woolfson is the Co-founder, Executive Chairman, and President of Replay. He was previously Executive Vice President and Head of R&D at Sangamo Therapeutics, leading programs in gene editing, the first in-human in vivo genome engineering studies, transcriptional repression, gene therapy, the first in-human autologous CAR-Treg study, and allogeneic CAR-T cell therapy.
Prior to that he was Chief Medical Officer of the 5AM-, LSP-, Abingworth- and Versant-backed cancer neoantigen vaccine company Nouscom, based in Basel, Switzerland and Rome, Italy, where he managed the transition of their lead melanoma neoantigen vaccine asset to IND. He was Global Clinical Leader of Early and Late Stage Immuno-Oncology/Hematology at Pfizer in New York, managing an I-O portfolio encompassing a broad range of immuno-modulatory assets tested in monotherapy and combination, including a PD-L1 antagonist (Bavencio), 4-1BB (CD137) agonist, (utomilumab), OX40 agonist and CAR-Ts, and built the Pfizer I-O hematological malignancies portfolio. Prior to that, he led the Ph3 registrational study for Pfizer’s Hedgehog pathway (SMO) inhibitor Daurismo, which received FDA approval in June 2020. Before this he held positions of increasing responsibility at Bristol-Myers Squibb in London UK, and Princeton New Jersey, where he was part of the team that successfully launched the Bcr-Abl inhibitor Sprycel.
His graduate and post-graduate medical training was in London, Oxford, and Cambridge, UK. His PhD thesis and post-doctoral work on molecular immunology was supervised by Nobel Prize winner, inventor of monoclonal antibodies, and discoverer of CD antigens, César Milstein. He was the Charles and Katharine Darwin Research Fellow at Darwin College Cambridge, UK, a Welcome Trust Clinical Research Fellow, and a National Foundation for Cancer Research Fellow at the MRC Laboratory of Molecular Biology in Cambridge, UK, where he worked on alternative splicing and protein folding. He is the author of over 140 publications, including two critically acclaimed books, book chapters, reviews, and peer-reviewed scientific papers. He is an author on multiple patents addressing the assembly of synthetic DNA, immune silencing, synthetic protein refolding machinery, and the barcoding of human diseases using machine learning and soluble proteins. He is a regular contributor to The Wall Street Journal, The Washington Post, and Science magazine, and contributes to a range of other publications including: Nature, The Spectator, The Financial Times, The Times Literary Supplement, and The Literary Review. He is on the Board of Directors of the Singapore and San Diego-based TCR drug discovery company ImmunoScape, and is a co-founder, Editorial Board member, and Books Review Editor of the GEN Biotechnology journal.
Host: Chris Ghadban
_______________________
Join BIOS Community 🎉
Become a member, continue the conversation, connect with like-minded Life Science innovators, access exclusive resources, & invite-only events…
Apply to Join -docs.google.com/forms/d/e/1FA...
For More Interesting Content 💭
🦾 Website: www.bios.community/
🧬 Podcast: open.spotify.com/show/2HmcPq9...
🧪 Medium: / bios
🩺 Twitter: / bios_community
🦠 LinkedIn: / bios-community
🧠 Substack: bioscommunity.substack.com
_______________________
BIOS: Nucleus of Life Science Innovation 🚀
Alix Ventures: Driving Patient Impact - Supporting Early Stage Startups Engineering Biology to Create Radical Advances in Human Health🌟 - วิทยาศาสตร์และเทคโนโลยี
